Debbie Rigby rounds up the latest in research news relevant to pharmacy
An updated Cochrane review on interventions to improve adherence to medications for atherosclerotic cardiovascular disease (ASCVD) secondary prevention identified three strategies that improve clinical outcomes. These included a short message service, a fixed dose combination pill and a community health worker-based intervention.
Heart. Published Online First: 23 March 2018.
This systematic review and meta-analysis of 15 RCTs involving 7122 patients with uncontrolled, persistent asthma has concluded that use of LAMA compared with placebo as add-on therapy to inhaled corticosteroids was associated with a lower risk of asthma exacerbations; however, the association of LAMA with benefit may not be greater than that with LABA. Triple therapy was not associated with a lower risk of exacerbations.
JAMA. Published online March 19, 2018.
This systematic review supports the combined use of inhaled corticosteroids and LABA as both the controller and quick relief therapy (SMART) among patients aged 12 years or older compared with using either the same or a higher dose of inhaled corticosteroids alone as the controller therapy or the same or a higher dose of inhaled corticosteroids and LABA as the controller therapy.
The efficacy of pharmacological treatments for patients with chronic low back pain is limited. The effects on pain reduction and improvement of function are commonly small to moderate and short lasting when compared to placebo. Prolonged use of opioids has the potential for serious side effects.
Expert Opinion on Pharmacotherapy, 2018.